Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals

Jagsonpal Pharmaceuticals Limited 

Jagsonpal Pharmaceuticals Limited had informed that the company had entered into an agreement to sell to divest the Faridabad Facility. The company has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities.

Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited has informed that the United States Food & Drug Administration (USFDA) has completed a GMP inspection at our API manufacturing facility (CTO-2) in Bollaram, Hyderabad. The inspection was conducted from 13th November, 2024 to 19th November, 2024. We have been issued a Form 483 with 7 observations, which we will address within the stipulated timeline.

Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited has entered into an exclusive Master Sales Agreement with Caregen Co., a leading South Korean company in the Nutraceuticals segment. Akums has been granted the exclusive rights to sell certain Caregen products in India, during the term of the agreement. Further the company shall also undertake the packaging, marketing and selling of Caregen’s line of bulk product under the Caregen’s trademark or Akums’s trademark or of Akums’s Clients trademark.

Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea.